Metabolism, excretion, and pharmacokinetics of (3-{[4-tert-butyl-benzyl)- (pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid, an EP2 receptor-selective prostaglandin E2 agonist, in male and female Sprague-Dawley rats

Drug Metabolism and Disposition

Volumn 33, Issue 8, 2005, Pages 1191-1201

  Johnson, Kim A ^a   Prakash, Chandra ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[[(4 TERT BUTYLBENZYL) (PYRIDINE 3 SULFONYL)AMINO]METHYL]PHENOXY]ACETIC ACID; ACETIC ACID DERIVATIVE; CARBON 14; CARBOXYL GROUP; CP 533 536; DRUG METABOLITE; GLUCURONIC ACID; HYDROXYL GROUP; PHENOL DERIVATIVE; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PYRIDINE; SULFATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONJUGATION; CONTROLLED STUDY; DEALKYLATION; DRUG EXCRETION; DRUG METABOLISM; FECES; FEMALE; HYDROXYLATION; ISOTOPE LABELING; MALE; NONHUMAN; OXIDATION; PLASMA CLEARANCE; PRIORITY JOURNAL; RADIOACTIVITY; RAT; RAT STRAIN; SEX DIFFERENCE; SINGLE DRUG DOSE; SULFATION;

ANIMALS; BILE; BIOTRANSFORMATION; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DINOPROSTONE; FECES; FEMALE; MALE; MASS SPECTROMETRY; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E; SEX FACTORS;

EID: 22944467535     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.105.004713     Document Type: Article

References (19)

1. Breyer RM, Bagdassarian CK, Myers SA, and Breyer MD (2001) Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41:661-690.
2. Carlin JR, Christofalo P, Arison BH, Ellsworth RE, Rosegay A, Miller RR, Chiu SHL, and Nandenheuvel WJA (1997) Disposition and metabolism of finasteride in dogs. Drug Metab Dispos 25:100-109.
3. Dix KJ, Coleman DP, and Jeffcoat AR (1999) Comparative metabolism and disposition of gemfibrozil in male and female Sprague-Dawley rats and Syrian golden hamsters. Drug Metab Dispos 27:138-146.
4. Jee WS and Ma YF (1997) The in vivo anabolic actions of prostaglandins in bone. Bone 21:297-304.
5. Johnson K, Prakash C, Shah A, Jaw J, and Baxter J (2003) Metabolism, pharmacokinetics and excretion of a highly selective NMDA receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers. Drug Metab Dispos 31:76-87.
6. Ke HZ, Shen VW, Qi H, Crawford DT, Wu DD, Liang XG, Chidsey-Frink KL, Pine CM, Simmons HA, and Thompson DD (1998) Prostaglandin E2 increases bone strength in intact rats and in ovariectomized rats with established osteopenia. Bone 23:249-255.
7. Kobliakov V, Popovaand N, and Rossi L (1991) Regulation of the expression of the sex-specific isoforms of cytochrome P450 in rat liver. Eur J Biochem 195:585-591.
8. Kulanthaivel P, Barbuch RJ, Davidson RS, Yi P, Rener GA, Mattiuz EL, Hadden CE, Goodwin LA, and Ehlhardt WJ (2004) Selective reduction of N-oxides to amines: application to drug metabolism. Drug Metab Dispos 32:966-972.
9. Lin J, Colizza K, and Prakash C (2003) Characterization of the unusual C-demethylated metabolites of the NK1 receptor antagonist, CJ-11,972, in human liver microsomes and 3A isoforms by LC-MS/MS, in Proceedings 51st ASMS Conference on Mass Spectrometry and Allied Topics, Montreal, Canada, June 8-12, 2003. American Society of Mass Spectrometry, Santa Fe, NM.
10. Maurizis JC, Madelmont JC, Rapp M, Marijnen C, Cerf MC, Gillardin JM, Lepage F, and Veyre A (1997) Disposition and metabolism of 2,6-dimethylbenzamide N-(5-methyl-3-isoxazoleyl) (D2916) in male and female rats. Drug Metab Dispos 25:33-39.
11. Melton LJ III (1995) Epidemiology of fractures, in Osteoporosis: Etiology, Diagnosis and Management, 2nd ed (Riggs BL and Melton LJ III, eds) pp 225-247, Lippincott-Raven Press, Philadelphia.
12. th ASMS Conference on Mass Spectrometry and Allied Topics, Dallas, TX, June 13-17, 1999. American Society of Mass Spectrometry, Santa Fe, NM.
13. Mugford CA and Kedderis GL (1998) Sex-dependent metabolism of xenobiotics. Drug Metab Rev 30:441-498.
14. Mulder G (1986) Sex differences in drug conjugation and their consequences for drug toxicity. Sulfation, glucuronidation and glutathione conjugation. Chem-Biol Interact 57:1-15.
15. Nakagomi M, Suzuki E, Kitashima M, Iida S, Abe M, Matsuki Y, and Kaneko K (1997) Sex difference in the metabolism of pirmenol in rats. Biol Pharm Bull 20:1279-1284.
16. 2 agonist induces bone healing. Proc Natl Acad Sci USA 100:6736-6740.
17. Prakash C, Cui D, Bright GM, Baxter J, Miceli J, and Wilner K (1998) Metabolism and excretion of a new anxiolytic drug candidate, CP-93,393, in healthy male volunteers. Drug Metab Dispos 26:448-456.
18. Prakash C, Kamel A, and Cui D (1997) Characterization of the novel benzisothiazole ring cleaved products of the antipsychotic drug, ziprasidone. Drug Metab Dispos 25:897-901.
19. Sato M, Suzaka H, and Miazaki H (2000) Sex-related differences in urinary excretion of egualen sodium in rats. Drug Metab Dispos 28:21-27.